Journal decision profile

Drug Delivery and Translational Research

Pharmacology, Toxicology and Pharmaceutics · Materials Science

Drug Delivery and Translational Research's 2026 Journal Metrics Score is 6.7, ranking Q1 in Pharmaceutical Science and 2 other subfields. Two-year citation average from OpenAlex data, updated August 2026.

Springer Science+Business MediaUnited StatespISSN 2190-393XeISSN 2190-3948
Checking system sharing availability.Visit homepage

Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.

Journal Metrics Score
i
Journal Metrics ScoreThe raw score is citations received in the latest complete year by works from the two previous years, divided by the number of those works. It is calculated from OpenAlex open data (CC0) and is not a percentage grade.
2026
6.7

Journal Metrics Score 2026 · 2021–2024 window citedness 6.19.

Submission-to-acceptance
i
Submission-to-acceptanceCalendar days between the received and accepted dates reported in recent PubMed records. This interval includes editorial handling and author revisions, so it is not time to first decision or pure peer-review time.
PUBMED
116 daysmedian

Middle 50%: 84–145 days

61 of 100 PubMed-indexed articles · 61% coverage · 2024–2025

Indicative APC
i
Indicative APCThis journal-level estimate comes from the OpenAlex source record. It is not a verified quote and may exclude taxes, waivers, society discounts, or article-type charges. Check the journal's official website before deciding.
OPENALEX · VERIFY
$4,190

Journal-level estimate only. Verify current charges, taxes, waivers, discounts, and article-type fees with the journal.

Free preview · no sign-in

Does your manuscript fit Drug Delivery and Translational Research?

Paste your title to see which of this journal's published topics it overlaps with. Your title stays in your browser for this preview and is not sent anywhere.

Want ranked journals with fit reasons, risks and a submission strategy instead? See a sample AI report.

At a glance

Journal decision profile

Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.

Relative profile

Metrics ScoreThe raw 2026 Journal Metrics Score is the recent two-year citation average shown above. The radar converts it to a 0–100 cohort percentile: farther out means a higher score than more comparable journals. It is not a percentage grade.iSource outputThe raw rank compares lifetime output inside the journal’s leading-topic source set. The radar then compares that rank position across Decision Profile journals in the same primary OpenAlex field; when that field has too few profiles, it uses the broader profile set. Farther out means relatively more output, not better research quality.iTop 10% shareThe share of recent papers in the global top 10% for citations after comparing papers of the same type, publication year, and subfield. The radar converts that share to a 0–100 cohort percentile; it does not predict how a new paper will perform.iMedian FWCICitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected citation level for comparable papers; the radar shows its 0–100 cohort percentile.iSubmission-to-acceptanceCalendar days from the received date to the accepted date in recent PubMed records. This includes editorial handling and author revisions, so it is not the time to first decision and not pure peer-review time. The radar uses a 0–100 cohort percentile with shorter observed timing plotted farther out; it does not measure review quality.iOutput volumeAverage works published per year in the recent analysis window, converted to a 0–100 cohort percentile. Farther out means the journal publishes more papers; it does not mean those papers are better.i
Cost is intentionally excluded. Missing APC data is never converted to a zero-dollar fee or a fabricated cost score.

Raw values behind the shape

Always visible
Metrics Score
i
Metrics ScoreThe 2026 raw Journal Metrics Score shown above. The bar is its 0–100 percentile within the radar's comparable journal cohort; it is not a percentage score.
6.72026 · OPENALEX
Source output rank
i
Source output rankThis lifetime journal-wide output rank compares works published by the OpenAlex source with sources associated with the journal’s leading topic. More output does not mean higher quality.
#104 / 1,017LIFETIME OUTPUT
Highly cited papers
i
Highly cited papersShare of recent works in the global top 10% for citations after comparing papers of the same type, publication year, and subfield.
25.5%FIELD-NORMALIZED TOP 10%
Field-normalized impact
i
Field-normalized impactCitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected level for comparable work.
1.48MEDIAN FWCI
Submission-to-acceptance
i
Submission-to-acceptanceReceived-to-accepted calendar days from qualified PubMed records. It includes editorial handling and author revisions; it is not time to first decision or pure peer-review time.
116 daysIQR 84–145 DAYS
Recent output
i
Recent outputAverage works published per year across the complete analysis window. This is a volume measure, not a quality score.
221 / yr2021–2024 AVG
Field-normalized top 10% share25.5%

226 of 885 works · same type, year & subfield

Field-normalized top 1% share2%

18 works · same type, year & subfield

Median FWCI1.48×

Above field-year expectation

Source output rank#104

of 1,017 topic-associated OpenAlex sources by lifetime output

What does Median FWCI mean?

FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 1.48, so its typical recent paper runs about 48% above its field benchmark.

What does Top 10% Share mean?

25.5% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.

Publishing pattern

Publication volume and article mix

Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.

Works published by year

OpenAlex source records · 2016–2025

782016
1182017
1432018
872019
1762020
2232021
1822022
2162023
2642024
2602025

Recent work-type mix

885 OpenAlex works · 2021–2024

Article95.1%
Erratum3.3%
Retraction0.7%
Editorial0.5%
Review0.3%
Book chapter0.1%
OpenAlex article is broader than “original research.” PubMed Publication Types can add case-report and clinical-study detail.
Fit signals

Topics and medical subject coverage

OpenAlex topics show research communities; MeSH keeps the medical taxonomy recognizable.

Major MeSH signals

PubMed-indexed works

Select a MeSH signal to see how much Drug Delivery and Translational Research publishes on it, from PubMed counts for the last five complete years.

Leading OpenAlex topics

2021–2024 works
Advancements in Transdermal Drug Delivery121
Nanoparticle-Based Drug Delivery83
Advanced Drug Delivery Systems62
RNA Interference and Gene Delivery44
Drug Solubulity and Delivery Systems34
Inhalation and Respiratory Drug Delivery22
3D Printing in Biomedical Research20
Extracellular vesicles in disease19
Nanoplatforms for cancer theranostics19
Immunotherapy and Immune Responses18
Methodology: OpenAlex snapshot 2026-08-12. FWCI, percentile badges, topics, and type mix use 885 works published 2021–2024. Radar normalization is versioned in the cached profile, and no cost score is assigned without reliable APC data.

Subject Category Quartiles

Quartiles computed within each OpenAlex subfield
CategoryQuartile
Pharmaceutical ScienceQ1
BiomaterialsQ1
Molecular BiologyQ1

Is Drug Delivery and Translational Research a good journal?

Yes. A Q1 journal by citation data

Yes. By citation data, Drug Delivery and Translational Research is a strong journal: it is Q1 in Pharmaceutical Science and 2 other subfields and ranks #12 of 207 Pharmacology journals by Journal Metrics Score (top 6%). Drug Delivery and Translational Research's 2026 Journal Metrics Score is 6.7. Recent papers took a median of 116 days from submission to acceptance, according to PubMed dates. OpenAlex lists an indicative article processing charge of $4,190 USD. OpenAlex classifies its papers in subfields including Pharmaceutical Science, Biomaterials, and Molecular Biology, so check that your topic fits its scope.

Best quartile
Q1
Pharmaceutical Science
Rank in Pharmacology
#12 of 207
Top 6%
2026 Journal Metrics Score
6.7
Acceptance rate
Not published
By the journal or publisher
Submission to acceptance
116 days
Median, PubMed records
Indicative APC
$4,190
OpenAlex, verify with the journal
Papers published in 2025
260
OpenAlex works

Check before you submit

  • Confirm the current article processing charge, waivers, and any institutional agreement on the journal website; the OpenAlex figure is indicative.
  • Confirm the journal is indexed where your institution or funder requires (for example Scopus or PubMed) before you submit.

Verdict from citation data only: quartile and field rank by Journal Metrics Score (OpenAlex), publisher-reported acceptance rates, and PubMed submission and acceptance dates. See how we rank journals and how to verify indexing.

Q1
Subfield Quartile
B3
CAS Block

Ranking and source check

#12
of 207 Pharmacology field journals
#12
among Q1 Pharmacology journals

Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.

Topics where this journal appears in PubMed searches

These topic links come from cached PubMed keyword snapshots where Drug Delivery and Translational Research is one of the leading matched journals.

Journal Details

OpenAlex Works
2,200
H-Index
90
Fully Open Access
No
Recent OA Works
885
Subject Areas
Pharmaceutical ScienceBiomaterialsMolecular Biology

Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.

How to submit to Drug Delivery and Translational Research

  1. 1

    Check the scope

    OpenAlex classifies Drug Delivery and Translational Research's papers in subfields including Pharmaceutical Science, Biomaterials, and Molecular Biology. Read the aims and scope page and a few recent papers close to your topic before you prepare the manuscript.

  2. 2

    Follow the author guidelines

    Article types, word and figure limits, reference style, and the required statements (data availability, ethics, conflicts of interest, author contributions) are set by the journal. Prepare the cover letter and files to match them.

    Drug Delivery and Translational Research homepage ↗
  3. 3

    Submit online

    Use the submit link in Drug Delivery and Translational Research's author guidelines; Springer Science+Business Media runs the submission site. Every author usually needs an ORCID iD, and the corresponding author needs an account on the submission site.

  4. 4

    Plan for costs

    OpenAlex lists an indicative article processing charge of $4,190 USD. Check the current fee, waivers, and any institutional agreement on the journal website.

  5. 5

    Know what to expect

    Recent accepted papers took a median of 116 days from submission to acceptance, including revisions (PubMed dates). Drug Delivery and Translational Research does not publish an acceptance rate.

New on PubMed

What's new in your field?

Type a topic to see the newest PubMed papers from the past week and the big picture of what they found, summarized by Claude on the Pro plan. Get a free weekly email to keep up.

See a demo:GLP-1CRISPRLong COVID

Reviewer Two · coming soon

Know what reviewers will say before you submit to Drug Delivery and Translational Research

An AI pre-submission report on your manuscript: the objections a tough reviewer is likely to raise, desk-rejection risks, and better-fit journals from our data. $29 per report.

See what the report covers

Common questions about Drug Delivery and Translational Research

Is Drug Delivery and Translational Research a good journal?

Yes. By citation data, Drug Delivery and Translational Research is a strong journal: it is Q1 in Pharmaceutical Science and 2 other subfields and ranks #12 of 207 Pharmacology journals by Journal Metrics Score (top 6%). Drug Delivery and Translational Research's 2026 Journal Metrics Score is 6.7. Recent papers took a median of 116 days from submission to acceptance, according to PubMed dates. OpenAlex lists an indicative article processing charge of $4,190 USD. OpenAlex classifies its papers in subfields including Pharmaceutical Science, Biomaterials, and Molecular Biology, so check that your topic fits its scope.

What is Drug Delivery and Translational Research's Journal Metrics Score in 2026?

Drug Delivery and Translational Research's 2026 Journal Metrics Score is 6.7, from the August 2026 data release. The score is a two-year citation average computed from OpenAlex (CC0) data: citations received in the most recent complete year to works published in the two prior years, divided by the number of those works.

What is the acceptance rate of Drug Delivery and Translational Research?

We have not found an official acceptance rate published by Drug Delivery and Translational Research or its publisher, and Journal Metrics does not estimate one because submission counts are not public. What recent PubMed records do show is speed: accepted papers took a median of 116 days from submission to acceptance. To judge selectivity, compare Drug Delivery and Translational Research's quartile and score with similar journals, or ask the editorial office.

What quartile is Drug Delivery and Translational Research in?

Drug Delivery and Translational Research's best quartile is Q1. By OpenAlex subfield: Q1 in Pharmaceutical Science; Q1 in Biomaterials; Q1 in Molecular Biology. Quartiles rank journals by Journal Metrics Score within each subfield.

Is the Journal Metrics Score the same as other journal citation metrics?

No. Journal Metrics computes the score independently from OpenAlex open data. Other providers use different citation databases, document types, and counting rules, so their published figures for Drug Delivery and Translational Research will not match this score exactly. Compare journals using one source at a time.

How long does Drug Delivery and Translational Research take from submission to acceptance?

Across 61 recent PubMed records with both dates, Drug Delivery and Translational Research took a median of 116 days from submission to acceptance; the middle half took 84–145 days. This interval includes editorial handling and revisions, so it is not the time to a first decision.

How much does it cost to publish in Drug Delivery and Translational Research?

OpenAlex lists an indicative article processing charge of $4,190 USD for Drug Delivery and Translational Research. This journal-level estimate may exclude taxes, waivers, discounts, or article-type fees, so confirm the current charge on the journal's website.

Which journals are alternatives to Drug Delivery and Translational Research?

Comparable journals include Pharmaceutics, International Journal of Pharmaceutics, Expert Opinion On Drug Delivery, and Rsc Pharmaceutics. Compare their scores, acceptance times, and costs in the recommended alternatives on this page before choosing where to submit.

How do I submit a paper to Drug Delivery and Translational Research?

Submit online through the link in Drug Delivery and Translational Research's author guidelines on the journal homepage. Before submitting, check the scope, follow the author guidelines for article type, length, and required statements, and prepare a cover letter. Accepted papers took a median of 116 days from submission to acceptance in recent PubMed records.

Cite an article from this journal
Back to Search